2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

4:30PM-6:00PM: Abstract Number: 2862

Diverse Disease Activity Measures Demonstrate That the Routine Assessment of Patient Index Data with 3 Measures (Rapid-3) Assesses Only Non Inflammatory Components of Disease and Should Not be Utilized in a Treat to Target Strategy in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

4:30PM-6:00PM: Abstract Number: 2873

DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

4:30PM-6:00PM: Abstract Number: 2878

Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2872

Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

4:30PM-6:00PM: Abstract Number: 2860

Enthesitis-Related Arthritis: Axial -Pattern Is Associated with an Expansion of Peripheral Th17 Populations .

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

4:30PM-6:00PM: Abstract Number: 2830

Epigenetic Cell Counting: A Novel Tool to Quantify Immune Cells in Salivary Glands Detects Robust Correlations of T Follicular Helper Cells with Immunopathology

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2856

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

4:30PM-6:00PM: Abstract Number: 2870

Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2832

Finding the Optimal Treatment Strategy for Disease Activity-Guided Dose Reduction of Adalimumab and Etanercept in Rheumatoid Arthritis: A Modelling Study

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2826

Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2851

General and Abdominal Obesity As Risk Factors for Late-Life Mobility Limitation Among Women with Total Knee or Hip Replacement for Osteoarthritis

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2834

Healthcare Cost Drivers in Rheumatoid Arthritis

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2882

IgG Galactosylation Status Combined with MYOM2 SNP Precisely Predicts Anti-TNF Response in Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2848

Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

4:30PM-6:00PM: Abstract Number: 2841

Infection Is the Major Trigger of Adult Hemophagocytic Syndrome, an Orphan Systemic Hyperinflammatory, Life-Threatening Disease: Analysis in 147 Patients (GEAS-SEMI Registry)

Infection-related Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].